FPH - Fisher Paykel Healthcare.

[lissica]

Weight loss drugs ?

"Despite their best efforts, 80% of people who lose weight regain itand many end up heavier within 5 years. Why? Our bodies fight back, revving up hunger while slowing metabolism after weight loss. In ongoing obesity discussions, ghrelin is in the spotlight as the "hunger hormone" playing a crucial role in driving appetite and facilitating weight gain. "

https://www.medscape.com/viewarticle...&impID=6666563

Obesity is a chronic illness, no different to diabetes, which these drugs also treat.

You don't stop medication just because the diabetes is under control.

[Panda-NZ-]

Obesity could be removed as an issue in (all?) developed and some middle income countries.

While America stands out with obese people plodding along because insurance deductibles, exclusions and lack of coverage.

[kiora]

Livewire plugging their sleep apnea again

"A MID-CAP STOCK DUE FOR A RE-RATE
ResMed (ASX: RMD)
Auscap’s thesis for this founder-led business, which sells CPAP (continual positive airway pressure) devices to sufferers of obstructive sleep apnoea (OSA), is built around ResMed’s dominance within its sector. Mumford emphasises its EPS has grown by 15% per annum for a decade, alongside a ROE of more than 20%.

He notes the large selloff of the share price in the last year – and again in recent weeks - in the wake of the perceived potential impact of GLP-1 drugs.

“Having spoken to many industry participants, we think the concerns are overblown,” Mumford says.
Reasons for this include potential side-effects of GLP-1s, treatment costs, and patient adherence.

“Feedback suggests that ResMed remains the strongly preferred CPAP standard of care, with physicians tending to view GLP-1s as an adjunctive OSA therapy to CPAP and demand trends for the CPAP sector remain extremely strong,” says Mumford.

“It also appears that the sudden focus on weight and health that has arisen from the GLP-1 fervour has substantially increased awareness of OSA, a particularly under-diagnosed condition, which is increasing the number of patients looking for a solution.”

He also refers to ResMed estimates that the potential global OSA market is approximately 1 billion people, with just 23.5 million people connected to ResMed devices as of FY23.

“ResMed is currently trading on a forward price to earnings multiple that is a significant discount to where it has traded historically, and even more so relative to the broader market, which we think is a great opportunity to buy in at an attractive price for long term investors,” Mumford says."

https://www.livewiremarkets.com/wire...rm=READ%20MORE

[kiora]

"New Samsung watches that detect sleep apnea should be good for sales"

[winner69]

Todays Market Report ….. At home, market leader Fisher and Paykel Healthcare was up 50c to $32.85 –it was last at that level in December 202

That’s pretty cool eh

Wonder if it’ll get to 35 bucks this month?